Failure mode studies have shown that patients with disease recurrence in the presence of drug-resistant tumor cells at the original site of disease and combined with P53 mutations are more susceptible to EGFR–TKI resistance (Tibdewal et al. 2021; Vokes et al. 2022). This evidence concerns the gene EGFR and neoplasm.